The role of various methods of kidney function assessment in dosing of oral anticoagulants in atrial fibrillation patients

Fedorova, D. N.; Лазарев, П. В.

doi:10.32756/0869-5490-2019-3-21-24

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Использование иных формул для оценки функции почек может потенциально привести к назначению избыточной или недостаточной дозы ППОАК (т. е. гипо-или гиперкоагуляции), а также применению этих препаратов при наличии противопоказаний к их приему. Если рассматривать количественные значения СКФ и КлКр в качестве категориальных величин (<30 мл/мин, 30-49 мл/мин, ≥50 мл/мин), применяемых у пациентов с ФП, то частота несоответствия формул CKD-EPI и Кокрофта-Голта может достигать 27,6-35,8% [48,49]. Следовательно, чтобы избежать ошибок при дозировании ППОАК, рекомендуется использовать формулу расчета КлКр по Кокрофту-Голту.…”

Section: классификационные вопросыunclassified

New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction

2020

View full text Add to dashboard Cite

Atrial fibrillation (AF) and chronic kidney disease (CKD) are common and interrelated diseases, the combination of which is associated with a poor prognosis. The efficacy and safety of direct oral anticoagulants (DOACs) used to prevent thromboembolic complications of AF may depend on renal function due to the specific pharmacokinetics of these drugs. This review considers current data on the role of kidneys in the pathogenesis of ischemic and bleeding events, methods of renal function assessment and related classification issues, as well as comparison of warfarin and DOAC therapy, in patients with AF and renal dysfunction of different stages based on the results of randomized controlled trials and actual clinical practice. DOAC use in the context of dynamic deterioration of renal function, supranormal renal function, and their effect on renal outcomes is discussed. International guidelines on anticoagulant therapy in AF and renal dysfunction were analyzed.

show abstract

Section: классификационные вопросыunclassified

New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction

2020

View full text Add to dashboard Cite

show abstract

Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation

Павлова

2022

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

The increase in the life expectancy of the population is accompanied by an increase in the prevalence of diseases for which old and senile age are risk factors. Atrial fibrillation (AF) and chronic kidney disease (CKD) are two diseases that can coexist in a patient. The risk of ac thromboembolic and hemorrhagic events in this case increases due to the mutual aggravating influence of these diseases. In addition, these patients have a high incidence of coronary events, and cardiovascular complications are the main cause of death in patients with AF and CKD. Consequently, such patients require an integrated approach to treatment, and their management is a complex clinical task. The direct oral anticoagulant rivaroxaban has been most studied in a population of comorbid AF and CKD patients and has proven a high efficacy and safety profile in these patients in randomized controlled trials. In addition, rivaroxaban has shown a significant reduction in the risk of myocardial infarction in various patients, as well as the possibility of preserving renal function to a greater extent compared with warfarin therapy, and a possible positive effect on reducing the risk of cognitive impairment. A single dosing regimen can improve adherence to treatment, which is one of the key conditions for achieving the above effects. Thus, these factors make it possible to achieve comprehensive protection of comorbid patients with AF and CKD.

show abstract

The role of various methods of kidney function assessment in dosing of oral anticoagulants in atrial fibrillation patients

Cited by 2 publications

References 10 publications

New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction

New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction

Renal Function Protection as an Important Component of a Comprehensive Approach to the Management of Patients with Atrial Fibrillation

Contact Info

Product

Resources

About